SEC Form 4 · accession 0001140361-17-046195
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Alecxih
Officer — Vice President, Sales
Period of report
Dec 12, 2017
Accepted (ET)
Dec 14, 2017 · 1:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 12, 2017 | A | 12,000 | $0.00 | A | 12,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $66.26 | Dec 12, 2017 | A | 45,000 | A | — | Dec 11, 2027 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on January 2 of each year, beginning January 2, 2019, subject to the Reporting Person's continued service to the issuer.
- F225% of the shares subject to the option vest on the first anniversary measured from December 12, 2017 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.